VEGF imaging for early breast cancer detection.
Completed
- Conditions
- breast cancercancer of the breast10006291
- Registration Number
- NL-OMON35509
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 47
Inclusion Criteria
Patients with a breast tumor who are scheduled to receive operative intervention either by means of a mastectomy or lumpectomy
Exclusion Criteria
• Other invasive malignancy or condition which could affect compliance with the protocol or interpretation of results.
• Pregnant or lactating women.
• Prior radiotherapy on the involved area.
• Major surgery within 28 days before the initiation of the study.
• Clinically significant cardiovascular disease.
• Prior allergic reaction to immunoglobulins or immunoglobulin allergy.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary endpoint will be 89Zr-bevacizumab tracer uptake in primary breast<br /><br>tumors</p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary endpoint will be 89Zr-bevacizumab tracer uptake in axillary lymph<br /><br>nodes. </p><br>